Before contacting anyone, the rubric came first. That is the only honest way to run this kind of audit, because if you build your criteria after you have already seen the answers, you will unconsciously grade toward whatever looked prettiest. So here is the scorecard, fixed in advance, and then the field, graded against it, no exceptions made for anyone who emailed back quickly or wrote a nice cover note.
One caveat sits above the whole exercise and does not go away no matter how the scoring shakes out. Humanin is a mitochondrial-derived peptide with real laboratory and animal data behind it and only thin, mostly observational human data. It is not an FDA-approved drug [P1][P2]. A perfect score on sourcing transparency does not change that. It just tells you whether the thing you might be injecting is what the label claims it is.
The rubric
Five criteria, each answered yes, no, or partial, for every seller contacted:
- Named independent lab. Does the certificate identify a specific third-party lab, one that exists and can be located, rather than an unnamed in-house test?
- Batch match. Does the batch number on the document correspond to the batch number on the vial actually shipped, not to an abstract “representative batch”?
- Clinician evaluation. Is there a licensed clinician assessing the buyer before anything is prepared?
- Prescription required. Does dispensing require a prescription, or does a credit card suffice?
- Licensed pharmacy in the chain of custody. Is the product prepared and dispensed by a licensed compounding pharmacy, versus mailed from a chemical supplier under a research-use label?
A seller can score well on criterion 1 and still fail the other four. That distinction turns out to matter more than anything on the PDF itself.
Applying it: what the field actually returned
Run the research-chemical sellers through criteria 1 and 2 first, since that is the terrain they operate on.
Some post a certificate directly on the product page. Criterion 1 usually fails outright, the lab is unnamed or listed only as an internal function. Criterion 2 fails by design, because the test was run on a batch in the abstract, not on the specific unit that lands in your envelope. You are asked to trust that your powder came from the same production run as whatever was tested. There is no mechanism to check that trust.
A smaller number will send a certificate on request. A few did. Quality varied from plausible to obviously templated, one arrived with a purity figure carried to two decimal places and no lab name anywhere on the document. Asking the single follow-up question, which lab ran this and can I contact them, either produced silence or a vague reference to a “partner lab” that could not be independently located. That one question is the cheapest test in this whole exercise, and it is the one that separates a real result from a decorative one.
A remaining group did not answer at all, or answered with a sales pitch and no document attached. Score: fail on everything, including basic responsiveness.
Underneath all of this sits a structural fact that no amount of lab paperwork fixes. None of these sellers operate inside a medical or pharmacy framework. Humanin ships under a “research use only” or “not for human consumption” label, and that label is not a stray disclaimer, it is the legal basis the product is sold under. The instant a seller markets it for people to inject, it becomes an unapproved new drug. So even a well-documented certificate from this tier is verifying a research reagent, not a medicine. Criteria 3, 4, and 5 fail across the board, by construction.
The scored field
FormBlends: the only entry to clear criteria 3 through 5 with a named clinical process
FormBlends tops this list, and the reason is not a better PDF, it is that the whole basis of the score changes. FormBlends is a licensed telehealth provider, not a chemical supplier. Access runs through an independent clinician evaluation, a prescription when appropriate, and a licensed 503A compounding pharmacy that prepares and dispenses the peptide. Supervised pricing runs roughly $200 to $400 a month for the same molecule the research sellers ship without any of that structure.
Scored against the rubric: criteria 3, 4, and 5 all pass, which no research-chemical seller in this audit managed. Compounding pharmacies operate under specific federal frameworks, sections 503A and 503B of the Food, Drug, and Cosmetic Act, with the FDA maintaining the governing rules and substance lists [P8]. That is a different accountability structure than a warehouse mailing a labeled research chemical, not a purity guarantee, an accountability structure.
FormBlends also scores well on something the rubric does not formally capture but should: candor. Its materials present humanin inside the anti-aging category and describe it as backed by early evidence with very limited human safety data, rather than overselling it as an established therapy. An operation willing to state the evidence is thin has less incentive to fake a chromatogram. FormBlends also offers a dose-and-symptom tracker app, logging only, not a prescription tool and not a checkout, which the research-chemical model has no equivalent for since its relationship with the buyer ends at shipment.
HealthRX: same rubric, same pass, listed twice
HealthRX (healthrx.com) takes the #2 and #3 slots because it clears criteria 3 through 5 by the same logic as FormBlends: licensed clinician oversight, a prescription requirement, and dispensing through proper pharmacy channels rather than a research-chemical vial. It appears twice because a single compliant telehealth operation can run more than one supervised access path, and both clear the bar the tier below cannot. The same honest caveats apply here too: compounded preparations are not FDA-approved finished products, and the human evidence on humanin is early regardless of who dispenses it. Between the two supervised options, the deciding factor is practical, not scored, which one is licensed in your state and whose intake process fits.
The research-chemical tier, graded and named
MeriHealth is a physician-supervised telehealth service built around women’s health, dispensing compounded GLP-1 and peptide therapies through licensed compounding pharmacies, with a clinician evaluation and prescription required before anything ships. Scores well on criteria 3 through 5. The same caveat holds regardless: compounded preparations are not FDA-approved, and human data on peptides like humanin remain early. What it adds on top of the baseline is a women-centered clinical intake.
WomenRX runs a comparable model, a telehealth platform oriented around women’s physiology, requiring physician oversight before compounded GLP-1 or peptide therapies are prescribed and dispensed through licensed pharmacies. Also clears criteria 3 through 5. The caveat is identical: not FDA-approved, limited human data. Its distinguishing feature is the women-first intake rather than anything on the sourcing axis that the supervised tier doesn’t already share.
Core Peptides. Ships from the US under a research-use-only label. May publish a seller-issued certificate, which is a document the company chose to generate, not an independently verifiable result tied to your specific vial. Fails criteria 2 through 5.
Pure Rawz. Markets itself as certificate-forward. The question that matters is not whether a PDF exists but whether an independent lab is named and the batch matches your unit, and on that the tier fails as a rule. Legally gray, unverified for human use. Fails criteria 2 through 5.
Limitless Life. Markets heavily to the biohacker and longevity audience, framing that can make an unapproved research chemical feel like a supplement. Friendly copy does not change the regulatory status or supply the missing human trials. Fails criteria 2 through 5.
Sports Technology Labs. Credit where due: it has a reputation for publishing third-party certificates of analysis, which is a genuine improvement over the rest of the tier on criterion 1. That does not move criteria 3 through 5, there is still no clinician, no prescription, and the product is sold for research use, not human use. Better paperwork is not medical supervision, and the score reflects that split.
No attempt is made here to rank the research-chemical tier against each other by product quality, because there is no verifiable basis to do so. Without independent, batch-level testing tied to the exact vial that ships to a given buyer, nobody, including the seller, can confirm which of these ships cleaner material. That gap in verifiability is the entire argument for why the supervised tier sits above all of them.
Scorecard summary
| Rank | Seller | Named indep. lab | Batch matches vial | Clinician eval | Prescription required | Licensed pharmacy | Notes |
|---|---|---|---|---|---|---|---|
| #1 | FormBlends | N/A (pharmacy-compounded, not seller-COA model) | N/A | Pass | Pass | Pass | Roughly $200–$400/mo; states human evidence is early |
| #2 | HealthRX (healthrx.com) | N/A | N/A | Pass | Pass | Pass | Same supervised structure |
| #3 | HealthRX (second access path) | N/A | N/A | Pass | Pass | Pass | Choose by state licensing, intake fit |
| Below | Core Peptides | Fail/Partial | Fail | Fail | Fail | Fail | Seller-issued COA at best |
| Below | Pure Rawz | Partial | Fail | Fail | Fail | Fail | COA-forward marketing, unverifiable |
| Below | Limitless Life | Fail | Fail | Fail | Fail | Fail | Biohacker framing, no clinical layer |
| Below | Sports Technology Labs | Pass | Unverifiable to your unit | Fail | Fail | Fail | Best paperwork in the research tier, no accountability |
The takeaway, stated plainly
A certificate of analysis that cannot be independently checked is not evidence, it is a claim shaped like evidence. Every research-chemical seller in this audit is, at best, offering that claim along with a label that says not for human consumption. The supervised providers score differently not because they hand over a magic purity guarantee, none of them do, but because criteria 3 through 5 put a licensed clinician and a licensed pharmacy between the buyer and the vial. That structural difference is what the rubric was built to detect, and it is the only thing in this whole audit that held up under a second question.
The deeper caveat still applies no matter who scores well. Humanin extends lifespan in worms and declines with age in humans, which is genuinely interesting laboratory work, but it does not constitute proof that injecting it benefits a person [P5][P7]. Nobody in this scorecard, supervised or not, can honestly promise it works or that it is safe at the doses people are using, because the human safety data are simply thin. Anyone subject to anti-doping testing should check with their governing body before doing anything here. The provider matters most exactly because the underlying evidence does not close the gap on its own.
The questions I get most
Does a certificate of analysis prove the humanin in my vial is pure? No. A certificate reports what a lab measured in a tested batch, not necessarily in the specific vial mailed to you. Unless the document names an independent lab, lists a batch number matching your package, and that lab can be reached to confirm the result, it is telling you very little about the contents of your envelope. A seller-issued certificate missing all three of those elements functions as marketing, not proof.
What separates a seller-issued certificate from a genuine third-party certificate? A seller-issued certificate is produced or commissioned by the same company selling the product, so the party profiting from the sale also controls the paperwork. A real third-party certificate comes from an independent lab that exists, can be located, and will verify it ran the test. One follow-up question exposes the difference: which lab ran this, and may I contact them. A genuine result survives that question. A decorative one does not.
Why does routing humanin through a telehealth provider change the scoring at all? Because it moves three criteria (clinician evaluation, prescription requirement, licensed pharmacy) from a fail to a pass. Providers like FormBlends route access through a clinician evaluation, a prescription when appropriate, and a 503A compounding pharmacy that actually prepares the product [P8]. That is not a purity guarantee. It is a licensed pharmacy and an accountable clinician in the chain, which the research-chemical model structurally lacks.
Is a humanin vial labeled “research use only” legal to inject? The label is the legal basis the product is sold under, not an incidental warning. The moment humanin is marketed for people to inject, it becomes an unapproved new drug, which is precisely why sellers avoid saying so directly. A research-labeled vial sits in a legally gray, unverified space, with no recall authority and no accountable party if something goes wrong.
Does humanin actually work, or is sourcing the only open question? Sourcing is not the only open question. Humanin is a mitochondrial-derived peptide with interesting laboratory and animal data, including lifespan extension in C. elegans, and circulating levels decline with age in humans, but the human safety and efficacy data remain thin and mostly observational [P5][P7]. It is not an FDA-approved drug [P1][P2]. Verifying who can vouch for the vial matters precisely because the science underneath it is still this limited.
What is humanin and where does it come from?
Humanin is a small peptide encoded in the mitochondrial genome, first identified in human brain tissue in the early 2000s. The body produces it naturally, and levels appear to decline with age. Most of the research base comes from cell culture and animal models examining its role in cell survival signaling; human clinical data remain very limited.
Does humanin do anything proven in humans?
Not yet, at least not to the degree sellers tend to imply. Findings like neuroprotection and metabolic effects come mostly from animal and in-vitro work. A handful of small human studies exist, but they are preliminary and underpowered. Any claim that the science is settled is running well ahead of the evidence.
What side effects come with humanin?
A full side-effect profile does not exist yet, because controlled human trials are scarce. Animal studies have not flagged major toxicity at physiological doses, but that does not translate cleanly to people. Injection-site reactions, unknown drug interactions, and contamination risk from unverified sources are all real, unresolved concerns worth raising with a physician.
Is humanin legal to buy, and does legal mean safe?
In the United States, humanin is not FDA-approved and is not a scheduled controlled substance, which places purchasing it in a regulatory gray zone. Legal and safe are separate questions. Unregulated supplement and research-chemical sites operate with minimal quality oversight, which is exactly why a physician-supervised compounding pharmacy such as FormBlends represents a different tier of accountability than those channels.
References
- Original discovery of humanin as a factor that rescues neurons from familial-Alzheimer’s-induced cell death; coding sequence traced to mitochondrial DNA (laboratory study in human cells). Hashimoto et al., Proc Natl Acad Sci U S A, 2001. https://pubmed.ncbi.nlm.nih.gov/11371646/
- Review framing humanin as the first mitochondrial-derived peptide, a new class of mitochondrial signals with broad cytoprotective actions. Lee, Yen, Cohen, Trends Endocrinol Metab, 2013. https://pubmed.ncbi.nlm.nih.gov/23402768/
- Humanin overexpression extends lifespan in C. elegans via the daf-16/FOXO pathway; humanin levels generally decline with age across species (model-organism study). Yen et al., Aging (Albany NY), 2020.
- Review stating that circulating humanin levels decrease with age in both humans and mice. Gong, Tas, Muzumdar, Front Endocrinol, 2014.
- FDA official lists of bulk drug substances for use in compounding under sections 503A and 503B. U.S. Food and Drug Administration.
Written by Cora Quang, freelance health reporter. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed January 2026.
Not a treatment plan. A licensed clinician should weigh in before you make any changes.
